Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayMay 16, 2017 12:20 pm

NetworkNewsBreaks – Great Basin Scientific, Inc. (GBSN) Commences Commercial Launch of Bordetella Direct Test in U.S.; Receives CE Marking in EU

Great Basin Scientific (OTCQB: GBSN) this morning said it is initiating the U.S. commercial launch of its Bordetella Direct Test. The company also said it has received CE Marking designation under the European Directive on In Vitro Diagnostic Medical Devices, marking the company’s sixth assay to receive CE Marking under the directive. The Bordetella Direct Test also increases the company’s commercially available assays in the U.S. to five. “The processes we put in place that resulted in a swift FDA clearance also supported our ability to quickly commercialize the Bordetella Direct Test, much to the relief of many of our…

Continue Reading

TuesdayMay 16, 2017 12:18 pm

NetworkNewsBreaks – Mirna Therapeutics, Inc. (NASDAQ: MIRN) Shares Plummet On Merger Agreement with Synlogic

Shares of Mirna Therapeutics (NASDAQ: MIRN) dropped 23% after the company announced its definitive merger agreement with Synlogic, Inc. Per the agreement, Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company will focus on advancing Synlogic’s drug discovery and development platform for Synthetic Biotic medicines and operate under the Synlogic name. Synlogic also recently closed a $42 million Series C preferred stock financing from leading biotechnology investors to finance the merged company. “Following a thorough review of strategic alternatives, we are delighted to announce this transaction with Synlogic, which we believe is…

Continue Reading

TuesdayMay 16, 2017 12:14 pm

NetworkNewsBreaks – ChinaNet Online Holdings (NASDAQ: CNET) Trims Net Loss, Increases Revenues in Q1 2017

ChinaNet Online Holdings (NASDAQ: CNET) this morning reported a 43.6% YoY increase in first-quarter revenues, sending shares 12% higher in mid-morning trade. For the three months ended March 31, 2017, total revenues increased to $7.3 million from $5.1 million in the prior year. The increase is primarily due to sales of the company’s search engine marketing, which increased 252.1% to $5.0 million. Alternatively, revenues from Internet advertising and data services were $2.3 million, a decrease of 36.8% from $3.6 million in the first quarter of 2016. Gross profit for the first quarter of 2017 was $1.3 million compared to $1.6…

Continue Reading

TuesdayMay 16, 2017 10:37 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Craig Cheifetz, M.D. to Advisory Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology. “I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies,” Ram Mukunda, CEO of IGC, stated in the news release. “We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions.” Cheifetz currently serves…

Continue Reading

MondayMay 15, 2017 4:27 pm

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Reports First Quarter 2017 Results, Management Reaffirms 2017 Guidance

Internet advertising company SRAX (NASDAQ: SRAX) today reported its first quarter 2017 financial results. Among the highlights, the company recorded quarterly revenue of $5.3 million with gross profit of $2 million. SRAX reported a net loss of $2 million for the three-month period, compared to a loss of $2.4 million in the first quarter of 2016. “Over the past year, we have expanded our offering, creating new high growth revenue streams like SRAX Reach, and established a leaner infrastructure,” Christopher Miglino, CEO and chairman of SRAX, stated in the news release. “While not evident in our first quarter financial results…

Continue Reading

FridayMay 12, 2017 12:58 pm

NetworkNewsBreaks – Capricor Therapeutics’ (NASDAQ: CAPR) ALLSTAR Trial Update Triggers Sell-off; Company to Focus on DMD, Trim Workforce

Shares of Capricor Therapeutics (NASDAQ: CAPR) dropped to a new 52-week low this morning – currently trading at $1.23 per share - after the company announced that six-month data of its ALLSTAR Trial demonstrated a low probability of achieving a statistically significant difference in its primary efficacy endpoint. "The lack of a clear difference in the change in scar size from baseline to six months between the active and control groups in the interim observations from ALLSTAR was unexpected. These results diverge from the consistent and extensive record of activity observed with our cell technology in the setting of cardiac…

Continue Reading

FridayMay 12, 2017 12:56 pm

NetworkNewsBreaks – Celsion Corporation (NASDAQ: CLSN) Shares Higher following Q1 Results, Development Program Update

Celsion Corporation (NASDAQ: CLSN) this morning posted its first-quarter results and issued an update on its lead program for ThemoDox®, currently in separate clinical trials for the treatment of primary liver cancer and recurrent chest wall breast cancer. Celsion’s immunotherapy program consists of GEN-1, currently in phase I development for the localized treatment of ovarian cancer. "Celsion continues to make major progress with respect to our ongoing global, pivotal Phase III OPTIMA Study in primary liver cancer.  This ground-breaking study continues to attract interest and support from the medical community, international regulatory agencies, and research organizations like the National Institutes…

Continue Reading

WednesdayMay 10, 2017 1:58 pm

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends Role of “Father of Marijuana Research” Raphael Mechoulam

In a news release issued early Tuesday, ABcann Global Corporation (TSXV: ABCN) announced that Raphael Mechoulam has agreed to extend his role as an advisor to the company. Aaron Keay, CEO and director of ABcann, spoke to the importance of this agreement in the news release. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history,” he stated. “The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has…

Continue Reading

WednesdayMay 10, 2017 10:46 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Launches Enhanced Aptito System alongside Nationwide Sales Campaign

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE) today announced significant enhancements to its cloud-based Aptito point-of-sale and mobile point-of-sale system. Some of the new features integrated into the platform as part of this update include enhanced options for reservations, bartending, reporting and kiosks; advanced printing, inventory and monitoring systems; the ability to import/export menus; the option to modify partially paid orders; and key enhancement pertaining to gift cards, inventory and system security. “A vast majority of restaurants are still using old legacy POS systems that fail to accommodate digital changes and consumer demands for convenience, speed, accuracy and…

Continue Reading

WednesdayMay 10, 2017 9:39 am

NetworkNewsBreaks – InMed Pharmaceuticals (IMLFF) Announces Filing of Provisional Patent for INM-085

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN) this morning announced the filing of a provisional patent application in the United States for INM-085 as a cannabinoid-based topical therapy for glaucoma. The company notes that this move marks an important step toward providing intellectual and commercial protection for INM-085. If approved, INM-085 could address an expansive global market that’s currently valued in excess of $5 billion. Per this morning’s update, glaucoma is currently the second-leading cause of blindness, driven by risk factors such as increased pressure in the eye, a family history of the condition, migraines, high…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000